Pfizer Makes Bold $7.3 Billion Move with Metsera Acquisition to Boost Obesity Drug Pipeline
Pfizer Makes Bold $7.3 Billion Move with Metsera Acquisition to Boost Obesity Drug Pipeline Pfizer has announced a significant strategic entry into the burgeoning obesity drug market with its intent to acquire biotech firm Metsera in a deal potentially valued at up to $7.3 billion. This acquisition, which includes future payments tied to clinical and regulatory milestones, positions Pfizer to aggressively compete in a sector projected to reach $100 billion by the 2030s. The pharmaceutical giant will initially pay $47.50…